{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"First Two Large Multinational Trials Validate Cardiovascular Safety of DPP-4 Inhibitors in the Treatment of Diabetes - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"l8m2kRn9b7\"><a href=\"https:\/\/themedicalxchange.com\/en\/2013\/10\/09\/european-society-of-cardiology-esc-congress-2013\/\">First Two Large Multinational Trials Validate Cardiovascular Safety of DPP-4 Inhibitors in the Treatment of Diabetes<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2013\/10\/09\/european-society-of-cardiology-esc-congress-2013\/embed\/#?secret=l8m2kRn9b7\" width=\"600\" height=\"338\" title=\"&#8220;First Two Large Multinational Trials Validate Cardiovascular Safety of DPP-4 Inhibitors in the Treatment of Diabetes&#8221; &#8212; The Medical Xchange\" data-secret=\"l8m2kRn9b7\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2013\/10\/MXCR-2341_ESC_Fig1_EN.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Amsterdam - Cardiovascular (CV) safety has been confirmed in the first two of a series of multinational studies conducted with dipeptidyl peptidase-4 (DPP-4) inhibitors. Four trials were launched in response to a U.S. Food and Drug Administration recommendation issued in 2008 that requested evidence of CV safety for any new antihyperglycemic agent. Each been powered to evaluate CV safety as a primary endpoint in high CV risk patients even though the CV safety signal from previously pooled phase 3 data post-hoc analyses had been encouraging. The two trials presented at the 2013 European Society of Cardiology (ESC) Congress provide the first validation of CV safety with DPP-4 inhibitors. Two more trials are underway. When all four trials are completed, an exceptionally large body of data will be available to judge both CV safety, which is the primary endpoint for each, and the overall tolerability of a class of drug."}